Qiagen NV | QIA - Selling And Administration Expenses


Qiagen NV reported $153.88M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
argenx SE USD 355M 74.62M Mar/2026
Avita Medical AUD 19.03M 1.95M Dec/2025
Dianthus Therapeutics USD 6.57M 1.62M Dec/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
IQVIA Holdings USD 502M 34M Mar/2026
Moderna USD 173M 135M Mar/2026
Organon & Co USD 433M 34M Dec/2025
Qiagen NV USD 153.88M 10.77M Dec/2025
Revvity USD 253.88M 2.15M Mar/2026
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Viatris USD 928.8M 101.9M Mar/2026
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025